Premium
Prenatal diagnosis of Duchenne muscular dystrophy in 131 Chinese families with dystrophinopathy
Author(s) -
Wang Huanhuan,
Xu Yan,
Liu Xiaoqing,
Wang Lei,
Jiang Wenting,
Xiao Bing,
Wei Wei,
Chen Yingwei,
Ye Weiping,
Ji Xing
Publication year - 2017
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.5019
Subject(s) - proband , duchenne muscular dystrophy , prenatal diagnosis , medicine , genetic counseling , germline mosaicism , genetic testing , muscular dystrophy , pediatrics , multiplex ligation dependent probe amplification , obstetrics , fetus , mutation , pregnancy , genetics , exon , biology , gene
Objectives The objective of this study is to report 6‐year clinical prenatal diagnosis experience of Duchenne muscular dystrophy (DMD)‐affected families evaluated at a single prenatal diagnosis center in China and establish a reliable and rational prenatal diagnosis procedure for DMD families. Methods The prenatal diagnosis data of 146 at‐risk pregnancies in 131 DMD families referred to our center from 2010 to 2016 were retrospectively reviewed. Results The mutation detection rate of the probands was greater than 99%. In the 131 families, 50 mothers showed negative results during carrier testing, and de novo exon deletions arose in 51.1% of the probands. Of the 146 pregnancies, 91 were male fetuses, 34 of which were affected. Germline mosaicism was identified three times in this cohort, and recombination of the DMD gene was detected in nine cases. Conclusions Accurate genetic diagnosis of the proband is important for preventing recurrence in at‐risk families. The present results demonstrate the importance of considering maternal germline mosaicism in the genetic assessment. Prenatal diagnosis should be suggested to the parent with a DMD proband whether carrier testing found the causative mutation in the mother's blood or not. Finally, we have developed a prenatal diagnosis algorithm for dystrophinopathies that combines multiplex ligation‐dependent probe amplification, quantitative PCR, sequencing and linkage analyses. © 2017 John Wiley & Sons, Ltd.